Last updated on April 2019

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations


Brief description of study

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Detailed Study Description

The purpose of this study is to evaluate the overall response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.

Clinical Study Identifier: TX152594

Find a site near you

Start Over

Meir Medical Center

Located in: Kfar-Saba, Israel
  Connect »

Chaim Sheba Medical Center

Located in: Ramat Gan, Israel
9.0miles
  Connect »

Tel Aviv Sourasky Medical Center

Located in: Tel Aviv-Yafo, Tel Aviv-Yafo Israel
9.77miles
  Connect »

Research Center

Located in: Ramat Gan, Israel
9.83miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.